Key Market Insights
- Over 185 non-viral transfection reagents are currently available in the market; of these, ~60% use lipid-based carriers to enable the transfection of genetic material
- In pursuit of building a competitive edge, industry stakeholders are actively enhancing their respective offerings to comply with the evolving industry benchmarks
- Over 20 electroporation-based systems and more than 35 other non-viral transfection systems have been developed for the delivery of DNA, RNA and protein fragments, in different types of cells
- Developers are focused on the integration of advanced features in their respective systems, in order to maintain their competitive position in the market
- The current market landscape of non-viral transfection and reagent developers features the presence of both established and emerging players, located across key global regions
- A notable increase in published scientific literature related to non-viral transfection methods and techniques has been observed in the past few years
- In the past four years, around 870 patents have been filed / granted related to non-viral transfection methods; of these, over 60% of the patents were by non-academic players
- Foreseeing a lucrative potential, big pharma players have also undertaken several initiatives focused on non-viral transfection; in the past two years, all collaborations inked by such players were focused on preclinical operations
- In order to optimize the price of advanced therapies, innovators are anticipated to forge alliances with non-viral transfection reagent and system developers
- Cost is a key determinant for the adoption of non-viral transfection techniques; the pricing strategy framework is likely to assist players in evaluating competitive prices for their reagents
- The market is likely to witness an annualized growth of ~10%; the projected opportunity is expected to be well distributed across different transfection methods, application areas, end-users and key geographical regions
Table of Content
- PREFACE
1.1. Chapter Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Transfection
3.3. Methods of Transfection
3.4. Applications of Transfection
3.5. Future Perspectives
- NON-VIRAL TRANSFECTION REAGENTS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Non-Viral Transfection Reagents
4.3 List of Non-Viral Transfection Reagent Suppliers
- ELECTROPORATION-BASED TRANSFECTION SYSTEMS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. List of Electroporation-based Transfection Systems
5.3. List of Electroporation-based Transfection System Suppliers
- OTHER NON-VIRAL TRANSFECTION SYSTEMS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. List of Other Non-Viral Transfection Systems
6.3. List of Other Non-Viral Transfection System Suppliers
- COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Non-Viral Transfection Reagent Suppliers: Company Competitiveness Analysis
- TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Electroporation-based Transfection Systems: Technology Competitiveness Analysis
8.4. Other Non-Viral Transfection Systems: Technology Competitiveness Analysis
- COMPANY PROFILES
9.1. Chapter Overview
9.2. Non-Viral Transfection Reagent Suppliers
9.2.1. MilliporeSigma
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Recent Developments and Future Outlook
9.3. Electroporation-based Transfection System Suppliers
9.4. Other Non-Viral Transfection System Suppliers
- POTENTIAL STRATEGIC PARTNERS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Non-Viral Transfection System Suppliers: Potential Strategic Partners in North America
10.4. Non-Viral Transfection System Suppliers: Potential Strategic Partners in Europe
10.5. Non-Viral Transfection System Suppliers: Potential Strategic Partners in Asia-Pacific and Rest of the World
- BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. None-Viral Transfection Reagents and System Suppliers: Big Pharma Initiatives
- PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Viral Transfection Reagents and Systems: Patent Analysis
12.4. Non-Viral Transfection Reagents and Systems: Patent Benchmarking Analysis
12.5. Non-Viral Transfection Reagents and Systems: Patent Valuation Analysis
- PUBLICATION ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Non-Viral Transfection Reagents and Systems: Recent Publications
13.4. Analysis by Year of Publication
13.5. Analysis by Type of Publication
13.6. Analysis by Type of Molecule Delivered
13.7. Analysis by Target Therapeutic Area
13.8. Analysis by Key Focus Areas (Word Cloud Representation)
13.9. Analysis by Prominent Cells and Cell Lines (Word Cloud Representation)
13.10 Leading Publishers: Analysis by Number of Publications
13.11. Prominent Journals: Analysis by Number of Publications
13.12. Prominent Copyright Holders: Analysis by Number of Publications
13.13 Key Funding Institutes: Analysis by Number of Publications
- ROOTS ANALYSIS PRICING STRATEGY FRAMEWORK
14.1. Chapter Overview
14.2 Roots Analysis Framework
14.3. Concluding Remarks
- MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Non-Viral Transfection Reagents and Systems Market, 2023-2035
15.4. Non-Viral Transfection Reagents and Systems Market: Analysis by Type of Non-Viral Transfection Method, 2023 and 2035
15.5. Non-Viral Transfection Reagents and Systems Market: Analysis by End-User, 2023 and 2035
15.6. Non-Viral Transfection Reagents and Systems Market: Analysis by Application Area, 2023 and 2035
15.7. Non-Viral Transfection Reagents and Systems Market: Analysis by Key Geographical Regions, 2023 and 2035
- EXECUTIVE INSIGHTS
- CONCLUSION
- APPENDIX I: TABULATED DATA
- APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/non-viral-transfection/307.html
Learn from experts: do you know about these emerging industry trends?
Adeno-Associated Viral Vectors: Unlocking the Future Opportunities
Modular Construction – Retrofitting Conventional Buildings
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
